Provided by Tiger Trade Technology Pte. Ltd.

Nurix Therapeutics

22.22
+0.01000.05%
Volume:331.69K
Turnover:7.33M
Market Cap:2.30B
PE:-6.52
High:22.69
Open:22.04
Low:21.23
Close:22.21
52wk High:28.23
52wk Low:9.00
Shares:103.41M
Float Shares:74.11M
Volume Ratio:1.27
T/O Rate:0.45%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4102
EPS(LYR):-3.0514
ROE:-80.30%
ROA:-40.06%
PB:5.71
PE(LYR):-7.28

Loading ...

Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NRIX), Taysha Gene Therapies (TSHA) and Zymeworks (ZYME)

TIPRANKS
·
Jul 01

Nurix Therapeutics assumed with an Outperform at Oppenheimer

TIPRANKS
·
Jun 29

Nurix Therapeutics (NRIX) Is Up 30.5% After Landmark Roche BTK Degrader Collaboration - What's Changed

Simply Wall St.
·
Jun 29

Nurix Therapeutics Chief Legal Officer Christine Ring Disposes of 28,935 Common Shares for $580,006

Reuters
·
Jun 26

Nurix Therapeutics Is Maintained at Outperform by Baird

Dow Jones
·
Jun 18

U.S. RESEARCH ROUNDUP- Datadog, Jabil, Prologis

Reuters
·
Jun 18

Stifel Nicolaus Sticks to Its Buy Rating for Nurix Therapeutics (NRIX)

TIPRANKS
·
Jun 15

Jefferies Sticks to Their Buy Rating for Nurix Therapeutics (NRIX)

TIPRANKS
·
Jun 15

Nurix Therapeutics Price Target Maintained With a $34.00/Share by Needham

Dow Jones
·
Jun 15

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jun 12

Nurix reports 22.1-month median PFS in Phase 1a trial of BTK degrader bexobrutideg for relapsed/refractory CLL/SLL

Reuters
·
Jun 11

Nurix Therapeutics - Reports 92.9% Objective Response Rate in Second Line Btki-Exposed, Bcl2i-NaÏVe Cll Patients

THOMSON REUTERS
·
Jun 11

Nurix Therapeutics - Responses Observed in High-Risk, Btk Resistant, and CNS-Involved Cll Subgroups

THOMSON REUTERS
·
Jun 11

Nurix Therapeutics - Phase 1a Data Shows 22.1 Month Median Pfs, 83% Orr in Heavily Pretreated Relapsed/Refractory Cll/Sll

THOMSON REUTERS
·
Jun 11

Nurix Therapeutics - Bexobrutideg Well Tolerated With Consistent Safety Profile

THOMSON REUTERS
·
Jun 11

Nurix Therapeutics to Report Updated Phase 1a/B Results for Btk Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory Cll/Sll and Promising Activity in Earlier Lines of Therapy

THOMSON REUTERS
·
Jun 11

Nurix Therapeutics Price Target Maintained With a $32.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 10

Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW), Nurix Therapeutics (NRIX) and Gilead Sciences (GILD)

TIPRANKS
·
Jun 09

Analysts Have Conflicting Sentiments on These Healthcare Companies: Nurix Therapeutics (NRIX) and Incyte (INCY)

TIPRANKS
·
Jun 09

Nurix Therapeutics price target raised to $45 from $41 at Jefferies

TIPRANKS
·
Jun 09